Table 2.
Summary of clinical cases of Cedecea lapagei
| Author | Year | Country | Age | Sex | Medical diagnosis | Clinical presentation | Comorbidities | Diagnostic method | Antimicrobial susceptibility testing (antibiogram) | Antibiotic treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Duperret et al.14 | 2020 | United States | 45 | Male | Sinusitis | Foul rhinorrhea, sinus headache, and fever | Asthma | Culture from purulent nasal secretions | Resistant to: amoxicillin/clavulanate, ampicillin, and cefazolin Sensitive to: ciprofloxacin, gentamicin, meropenem, tetracycline, and tobramycin Intermediate sensitivity to: cefuroxime | Oral ciprofloxacin + nasal gentamicin/dexamethasone | Patient recovered (discharged) |
| Hai et al.7 | 2020 | Vietnam | 38 | Male | Pneumonia and septic shock | Fatigue, cough, sputum, myalgia, fever, and shortness of breath | Diabetes mellitus type 2 | Sputum culture | Resistant to: trimethoprim/ sulfamethoxazole Sensitive to: piperacillin/ tazobactam, ceftazidime, ceftriaxone, cefazolin, cefoxitin, aztreonam, imipenem, meropenem, amikacin, gentamicin, tobramycin, levofloxacin, and ciprofloxacin Intermediate sensitivity to: piperacillin | IV meropenem + IV ciprofloxacin | Patient recovered (discharged) |
| Ramaswamy et al.15 | 2019 | India | 35 days | Male | Nosocomial pneumonia and sepsis | Poor peripheral pulses, lethargy, fever, and severe respiratory distress | Late preterm | Blood culture | Resistant to: meropenem, colistin, amikacin, gentamycin, and ceftazidime Sensitive to: piperacillin, piperacillin/ tazobactam, trimethoprim/ sulfamethoxazole, ciprofloxacin, and levofloxacin | IV piperacillin/ tazobactam | Patient recovered (discharged) |
| Chavez Herrera et al.16 | 2018 | Mexico | 52 | Male | Infection of hemorrhagic bullae causing necrotizing fasciitis and septic shock | Fever, pain, edema in his right lower limb, and multiple organ failure | Liver cirrhosis and treated hypertension | Bullae fluid culture | Resistant to: ampicillin, cefazolin, and imipenem Sensitive to: amikacin, aztreonam, ceftriaxone, ceftazidime, cefotaxime, ciprofloxacin, cefepime, cefuroxime, cefotetan, gentamicin, levofloxacin, meropenem, moxifloxacin, and piperacillin/ tazobactam Intermediate sensitivity to: ampicillin/sulbactam | IV clindamycin + IV ceftriaxone | Death |
| Kury et al.17 | 2017 | Brazil | 110 days | Male | Ventilator-associated pneumonia and sepsis | Fever and yellow sputum | Ischemic encephalopathy sequelae and chronic lung disease | Cultures from blood and tracheal aspirates | Resistant to: NR Sensitive to: piperacillin, imipenem, amikacin, gentamycin, ciprofloxacin, levofloxacin, meropenem, and trimethoprim/ sulfamethoxazole | IV meropenem | Patient recovered (discharged) |
| Biswal et al.18 | 2015 | India | 50 | Male | Ulcer and pus formation at the cancer site | Fever and pain at the local site of ulcer, radiating to ear and forehead | Squamous cell carcinoma of the right buccal mucosa undergoing chemotherapy | Culture of pus samples from the ulcer site | Resistant to: ampicillin/sulbactam, tetracycline, and tigecycline Sensitive to: amikacin, gentamicin, ceftazidime, ceftriaxone, cefepime, ciprofloxacin, meropenem, and trimethoprim/ sulfamethoxazole | IV ciprofloxacin | Patient recovered (discharged) |
| Salazar et al.6 | 2013 | Ecuador | 24 | Male | Traumatic wound infection | Fever, poor condition of healing tissue, increased discharge, and bad odor | No comorbidities | Culture of secretion obtained from granulation tissue | Resistant to: ampicillin and ampicillin/ sulbactam Sensitive to: cefuroxime, amikacin, trimethoprim/ sulfamethoxazole, ciprofloxacin, cefotaxime, carbapenems | IV ampicillin/sulbactam | Patient recovered (discharged) |
| Hong et al.19 | 2015 | South Korea | 76 | Male | Pneumonia | Fever and dyspnea | Chronic obstructive pulmonary disease | Sputum culture | Resistant to: amoxicillin/clavulanate and cefoxitin Sensitive to: piperacillin, cefotaxime, ceftazidime, cefepime, imipenem, amikacin, ciprofloxacin, tetracycline, and trimethoprim/ sulfamethoxazole | IV cefpodoxime | Patient recovered (discharged) |
| Sanchez-Lopez et al.5 | 2013 | Mexico | 34 | Male | Pneumonia | Fever, dyspnea, bilateral alveolar infiltrates, copious yellow sputum, and disseminated intravascular coagulation | Acute promyelocytic leukemia | Sputum culture | Resistant to: amikacin, ampicillin, aztreonam, cefazolin, cefepime, ceftriaxone, ciprofloxacin, ertapenem, imipenem, meropenem, moxifloxacin, nitrofurantoin, piperacillin/ tazobactam, and trimethoprim/ sulfamethoxazole Sensitive to: tigecycline Intermediate sensitivity to: ampicillin/sulbactam, gentamicin, and tobramycin | IV cefepime + IV vancomycin | Patient recovered (discharged) |
| Yetkin et al.20 | 2008 | Turkey | 38 | Male | Pneumonia from the aspiration of upper airway secretion | Fever, dyspnea | Subarachnoid hemorrhage and chronic obstructive pulmonary disease | Culture from bronchoalveolar lavage fluid | Resistant to: amoxicillin, ampicillin, amoxicillin/clavulonate, and cephalothin Sensitive to: amikacin, ciprofloxacin, trimethoprim/ sulfamethoxazole, imipenem, aztreonam, cefepime, ceftriaxone, ceftazidime, cefotaxime, cefuroxime, piperacillin / tazobactam, gentamicin, piperacillin, and tetracycline | IV amikacin + IV vancomycin + IV meropenem | Death |
| Dalamaga et al.21 | 2008 | Greece | 47 | Male | Wound infection | Fever, full-thickness burns in the right knee, and erythema, vesicles, and ulcerations in the left knee | Diabetes mellitus type 2 | Blood and wound cultures | Resistant to: gentamicin, tobramycin, cephalothin, cefuroxime, cefoxitin, ceftazidime, tetracycline, and ampicillin Sensitive to: amikacin, meropenem, cefotaxime, cefepime, aztreonam, amoxicillin/clavulanate, piperacillin/tazobactam, trimethoprim/ sulfamethoxazole, ciprofloxacin, and levofloxacin | IV cefotaxime + IV amikacin | Patient recovered (discharged) |
| Davis and Wall4 | 2006 | United States | 55 | Male | Peritonitis | Fever, abdominal pain, and cloudy dialysis effluent | Hypertension, orthotopic liver transplantation secondary to cirrhosis related to hepatitis C, continuous peritoneal dialysis, and end-stage renal disease secondary to glomerular disease | Culture from peritoneal fluid | NR | IV vancomycin + IV gentamicin | Patient recovered (discharged) |
| Mohamud et al.22 | 2022 | Somalia | 55 | Male | Urinary tract infection | Acute exacerbations of renal failure and irritative voiding symptoms | Chronic renal failure, uncontrolled diabetes mellitus type 2, and hypertension | Culture from urine | Resistant to: ceftriaxone, cefazolin, ceftazidime, cefixime, ampicillin, and amoxicillin/clavulanate Sensitive to: amikacin, gentamicin, trimethoprim/ sulfamethoxazole, ciprofloxacin, levofloxacin, imipenem, and ertapenem | Oral levofloxacin | Patient recovered (discharged) |
| Cárdenas et al.23 | 2015 | Colombia | 47 | Male | Acute osteomyelitis | Fever, edema, and erythema in the surgical area | No comorbidities | Culture from bone biopsy | Sensitive to: ertapenem | IV oxacillin + rifampicin empirically, switched to ertapenem after culture | Patient recovered (discharged) |
| Arellano Aguilar et al.28 | 2016 | Mexico | 67 | Female | Bacteremia and burns on 20% of body surface | Burns in the granulation stage with moderate edema | Diabetes mellitus type 1, hypertension, and dyslipidemia | Culture from bronchial aspirate and blood culture | Resistant to: ampicillin, amikacin, and piperacillin/ tazobactam Sensitive to: meropenem and imipenem | IV piperacillin/ tazobactam + caspofungin initially, switched to linezolid on day 20 + imipenem/cilastatin on day 24 | Patient recovered (discharged) |
| Çekin et al.24 | 2014 | Turkey | 40 | Male | Urinary tract infection | Fever | Quadriplegia and use of urinary catheter | Culture from urine | Resistant to: ampicillin, gentamicin, tobramycin, cefazolin, cephalothin, amikacin, ampicillin/sulbactam, ertapenem, imipenem, meropenem, piperacillin, piperacillin/ tazobactam, cefepime, cefoxitin, cefotaxime, cefuroxime, and aztreonam Sensitive to: ciprofloxacin, levofloxacin, and trimethoprim/ sulfamethoxazole | IV ciprofloxacin | Patient recovered (discharged) |
| Islam et al.25 | 2016 | India | First hours of life | Female | Sepsis with pneumonia | Respiratory distress immediately after birth | Meconium-stained amniotic fluid and low birth weight | Blood culture | Resistant to: amoxicillin/clavulonate, ceftazidime, ceftriaxone, trimethoprim/sulfamethoxazole, gentamycin, cefuroxime, and piperacillin/tazobactam Sensitive to: ciprofloxacin and imipenem | IV amikacin + IV ciprofloxacin | Patient recovered (discharged) |
| Ahmad et al.8 | 2017 | India | 26 days | Female | Late-onset sepsis | NR | Preterm, apnea | Blood culture | Resistant to: imipenem, meropenem, aztreonam, ceftazidime, cefotaxime, cefoxitin, cefepime, and cefoperazone/sulbactam | IV cefotaxime + IV amikacin | Patient recovered (discharged) |
| Deveci and Arpag26 | 2021 | Turkey | 76 | Male | Pneumonia | Fever, shortness of breath, cough, sputum, wheezing, and impaired consciousness | COVID-19 2 weeks ago | Sputum culture | Resistant to: amoxicillin/clavulanate, piperacillin/ tazobactam, cefuroxime, cefuroxime acetil, ceftriaxone, ceftazidime, cefepime, amikacin, gentamicin, ciprofloxacin, tigecycline, and colistin Intermediate sensitivity to: meropenem and trimethoprim/ sulfamethoxazole | IV meropenem + IV moxifloxacin | Patient recovered (discharged) |
| González Rivera et al.27 | 2022 | Mexico | 57 | Male | Pneumonia and septic shock | Fever, dyspnea, decreased amplection, use of accessory musculature with oxygen through nasal prongs at 5 L per minute, increased vocal vibrations on palpation, and bilateral infrascapular crepitant rales | HIV treatment discontinuation for the last 3 years | Culture from bronchial aspirate | Resistant to: ampicillin, gentamicin, tobramycin, cefazolin, cephalothin, amikacin, ampicillin/sulbactam, ertapenem, imipenem, meropenem, piperacillin, cefepime, cefotaxime, cefuroxime, aztreonam, ciprofloxacin, levofloxacin, and trimethoprim/ sulfamethoxazole | NR | Death |
IV = intravenous; NR = not reported. Age is shown as years unless otherwise noted.